Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
An irregular broad-complex tachycardia in a patient with pre-excitation may be pre-excited AF and can deteriorate to ventricular fibrillation. If unstable, perform immediate synchronised cardioversion; if pulseless, follow the shockable cardiac-arrest algorithm.
Synopsis
Recognise ventricular pre-excitation, manage AV re-entry and pre-excited atrial fibrillation safely, and identify who needs electrophysiology risk assessment or ablation.
Pre-excitation means an accessory atrioventricular pathway conducts to the ventricle outside the AV node; WPW syndrome is pre-excitation plus symptomatic tachyarrhythmia.
The sinus-rhythm ECG classically shows a short PR interval, slurred initial QRS upstroke (delta wave) and a widened QRS.
Orthodromic AV re-entrant tachycardia is usually regular and narrow because antegrade conduction uses the AV node; antidromic AVRT is broad.
Key red flags
Pre-excited AF
An irregular broad tachycardia with changing QRS morphology and very short RR intervals is the critical pattern.
Investigation priorities
01
12-lead ECG in sinus rhythmFirst step
Confirm and localise pre-excitation and look for alternative conduction disease.
Management branches
regular-narrowStable regular narrow tachycardia
The rhythm is regular, QRS is under 120 ms and there is no evidence of pre-excited AF.
Record a 12-lead ECG and perform vagal manoeuvres while monitoring continuously.
If unsuccessful and there is no pre-excitation in the tachycardia, give adenosine 6 mg as a very rapid IV bolus followed by a flush.
Key medicines
AdenosineRCUK March 2026: 6 mg by very rapid IV bolus, then 12 mg if unsuccessful, then 18 mg if still unsuccessful, each followed by a rapid flush and given with continuous ECG recording. This resuscitation-algorithm sequence differs from the cited product SmPC's licensed 3 mg, 6 mg, then 12 mg sequence.
ProcainamideRCUK: 10-15 mg/kg IV over 20 minutes, maximum 1 g, with continuous ECG and blood-pressure monitoring.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
eMC: Adenosine 3 mg/mL injection SmPCProduct-specific licensed dosing, contraindications and dipyridamole interaction, contrasted with the current RCUK algorithm.